Celltrion (068270 KS): Humira Biosimilar Launch in US; Filed New Biosimilar Marketing Application
Celltrion has launched Humira biosimilar Yuflyma in the US, with a list price of $6,576.50 per month, 5% cheaper than Humira. The company filed for...
451 Views
CFD Liquidation in Korea: Posco DX, Celltrion Siblings, and Potential Next Targets
This post investigates what might have happened to Posco DX today and Celltrion siblings yesterday, which are suspected of being the victim of CFD...
588 Views
Celltrion Healthcare (091990 KS): Portfolio Enhancement to Drive Business Growth
Celltrion Healthcare is expected to launch Humira biosimilar in US in July 2023. Through portfolio expansion, Celltrion aims to increase target...
487 Views
Korea: What Are Foreign Investors Buying & Selling?
Foreign investors have been buying stock in Korea and hold 32% of the KOSPI market cap and 8.5% of the KOSDAQ market cap. There is a big dispersion...
623 Views
SK Pharmteco Pre-IPO Funding & Impact on SK Inc
SK Pharmteco is seeking valuation of about 5 trillion won which is much higher than its book value of 1.65 trillion won. SK Pharmteco (100% owned...
548 Views